Feasibility and accuracy evaluation of three human papillomavirus assays for FTA card-based sampling: a pilot study in cervical cancer screening

Shao-Ming Wang¹, Shang-Ying Hu¹, Wen Chen¹, Feng Chen¹, Fang-Hui Zhao¹, Wei He¹, Xin-Ming Ma¹, Yu-Qing Zhang¹, Jian Wang¹,², Priya Sivasubramaniam¹,³ and You-Lin Qiao¹*

Abstract

Background: Liquid-state specimen carriers are inadequate for sample transportation in large-scale screening projects in low-resource settings, which necessitates the exploration of novel non-hazardous solid-state alternatives. Studies investigating the feasibility and accuracy of a solid-state human papillomavirus (HPV) sampling medium in combination with different down-stream HPV DNA assays for cervical cancer screening are needed.

Methods: We collected two cervical specimens from 396 women, aged 25–65 years, who were enrolled in a cervical cancer screening trial. One sample was stored using DCM preservative solution and the other was applied to a Whatman Indicating FTA Elute® card (FTA card). All specimens were processed using three HPV testing methods, including Hybrid capture 2 (HC2), careHPV™, and Cobas®4800 tests. All the women underwent a rigorous colposcopic evaluation that included using a microbiopsy protocol.

Results: Compared to the liquid-based carrier, the FTA card demonstrated comparable sensitivity for detecting high grade Cervical Intraepithelial Neoplasia (CIN) using HC2 (91.7 %), careHPV™ (83.3 %), and Cobas®4800 (91.7 %) tests. Moreover, the FTA card showed a higher specificity compared to a liquid-based carrier for HC2 (79.5 % vs. 71.6 %, P = 0.015), comparable specificity for careHPV™ (78.1 % vs. 73.0 %, P > 0.05), but lower specificity for the Cobas®4800 test (62.4 % vs. 69.9 %, P = 0.032). Generally, the FTA card-based sampling medium’s accuracy was comparable with that of liquid-based medium for the three HPV testing assays.

Conclusions: FTA cards are a promising sample carrier for cervical cancer screening. With further optimization, it can be utilized for HPV testing in areas of varying economic development.

Keywords: Whatman Indicating FTA Elute® card (FTA card), Cervical cancer screening, careHPV™, Cobas®4800, Hybrid capture 2 (HC2)

Background

Cervical Cancer is the fourth most common cancer of women worldwide. An estimated 528,000 new cases and 266,000 deaths from cervical cancer occur annually, among which 85 % occur in developing countries. China, a developing country with high cervical cancer incidence (7.5/100,000) and mortality (3.4/100,000), bears a substantial burden of cervical disease [1, 2].

Current evidence shows that persistent infection with carcinogenic human papillomavirus (HPV) types is the cause of virtually all cervical cancer [3]. Consequently, HPV DNA testing was explored as one of the primary cervical cancer screening methods in several countries [4]. In developing countries like China, where critical infrastructure is not available, screening by gynecologists and cytologists is generally inefficient and unworkable.
Expanding the coverage of objective HPV testing methods is a more expeditious and effective way to introduce large-scale of cervical cancer screening. Combining cervical sample collection with regional or centralized HPV detection could be an efficient way to increase screening coverage in such areas. However, most current HPV testing methods utilize a liquid-based sample carrier, which is limited by large sample volumes, risk of leakage, and challenges with storage and transportation, especially in remote rural areas.

Solid-state specimen carriers, such as the Whatman Indicating FTA Elute™ card (FTA card, GE Healthcare, Buckinghamshire, UK), provide an alternative sampling medium for DNA sample collection. FTA cards provide a cost effective room temperature method for collecting, shipping, archiving and processing nucleic acids from a wide variety of biological samples. The cards contain an inert dye that changes from purple to white indicating the location of a clear, colorless sample. Moreover, indicating FTA Elute cards facilitate rapid purification of nucleic acids in less than 30 min per sample and provide DNA in solution for multiple amplification reactions with high stability. There is evidence that genomic DNA stored on FTA cards at room temperature for more than 17.5 years still can be successfully amplified by PCR. FTA cards have been used in forensic science for DNA sample collection and storage for decades, but it has only recently been explored as an alternative to current liquid-based sampling mediums for cervical cancer screening [5–9].

A few studies have investigated the FTA cards with PCR-based detection methods or a single HPV DNA testing method with high clinical sensitivity and specificity [5, 9–12]. However, no published study has made a direct comparison of FTA cards and liquid sampling medium using the predominant clinical HPV testing methods.

Therefore, our project sought to investigate the feasibility of using FTA cards as an HPV sampling medium for cervical cancer screening. We also explored the compatibility of FTA cards with the predominant clinical HPV DNA assays.

**Methods**

**Study population**

Samples were collected among women enrolled in “LCMCCSS”, a large population-based screening trial in rural China, which was a collaboration between the Cancer Institute, Chinese Academy of Medical Sciences (CICAMS) and the Program for Appropriate Technology in Health (PATH) [13, 14]. Eligible women were ages 25–65 years, not pregnant and did not have a history of diagnosed Cervical Intraepithelial Neoplasia (CIN), cervical cancer, or hysterectomy. After a socio-demographic questionnaire survey, each woman provided one self-collected and two clinician-collected specimens. The self-collected specimen and one clinician-collected specimen were tested by careHPV™ and Hybrid Capture 2 (Qiagen, Gaithersburg, MD, USA); the other clinician-collected specimen was tested for HPV16/18/45 E6 protein with the OncoE6™ Cervical test (Arbor Vita Corporation, Sunnyvale, CA, USA). After sample collection, women were screened by visual inspection with acetic acid (VIA). One to two weeks later, women who tested positive for any of the six screening tests performed (VIA, HPV E6, and HC2 and careHPV™ on clinician-collected and self-collected specimens) and approximately a 10% random sample of women who tested negative for all screening tests (screen-negative women) were called back to undergo a second VIA and a rigorous colposcopic evaluation. All colposcopically detected abnormalities (acetowhite lesions) were biopsied. If the colposcopic examination showed no lesion in a quadrant but any of the screen results was positive, a random biopsy was obtained at the squamocolumnar junction in that quadrant at 2, 4, 8, or 10 o'clock. An endocervical curettage (ECC) was performed after the cervical biopsies. Women who were screen negative and were without any colposcopic indications of abnormality did not undergo colposcopically-directed biopsies.

**Sample collection**

We conducted our study among women who returned for colposcopy in LCMCCSS between May and June 2012. Recruitment was stopped when the target sample size (n = 396) was reached. The population included 207 women who were HPV positive, 17 women who were VIA positive (including 10 HPV positive women) and 182 randomly selected normal women. Ethics approval was obtained from the Ethics Committee of Cancer Institute and Hospital, Chinese Academy of Medical Sciences (Approval No. 12-040/574). Written Informed consent was obtained from each subject. One liquid sample was collected by a physician using a Conical Cervical Sampler (Qiagen, Gaithersburg, MD, USA) and was stored in DCM preservative solution (Qiagen, Gaithersburg, MD, USA). A second sample was collected by a physician using a new Conical Cervical Sampler and applied to an FTA card, which will be referred to as the “solid sample” in this study. All the samples were stored at room temperature and analyzed in the CICAMS central laboratory. All the women underwent a rigorous colposcopic evaluation that included using a microbiopsy protocol as previously described [13, 15]. A CICAMS pathologist was responsible for reporting the results and high grade CIN case confirmation (see Fig. 1).
Liquid sample detection
HC2, the first HPV DNA testing method approved by the United States Food and Drug Administration for clinical use, utilizes hybrid capture technology to detect 13 carcinogenic HPV genotypes. HC2 testing was conducted per the manufacturer’s instructions, with one exception: 50 μl of the DCM specimen was combined with 25 μl of the kit denaturation reagent rather than combining 1000 μl of STM specimen with 500 μl of the kit denaturation reagent. careHPV™ is a newly-developed and promising screening system developed for low resource regions. Its workflow is similar but simpler than the HC2 test with a lower cost and simpler administration. careHPV™ testing was conducted according to the manufacturer’s instructions as previously described [16]. A signal strength of 1.0 relative light units per positive control (rlu/pc) or greater was considered positive for both tests. The Cobas®4800 test (Roche Molecular Systems, Pleasanton, CA) is a widely-used, PCR-based testing method with high clinical sensitivity and specificity [17, 18]. It can detect 14 types of high-risk HPV and requires a lower number of DNA copies as compared to the HC2 test. Since the manufacturer did not provide instructions for DCM-based sample detection, CICAMS developed the workflow according to several small pilot studies. DCM preservative solution was diluted 10 times with sterilized PBS buffer, referring to careHPV™ which had approved commercial instructions for DCM samples. Thereafter, DNA extraction and PCR amplification were performed according to the manufacturer’s instructions.

FTA card sample detection
In order to ensure a high degree of accuracy, CICAMS and GE Healthcare performed pilot tests to develop optimized protocols for use of FTA cards with the three HPV assays. FTA cards were punched using a specifically designed sterilized perforator (3-mm Harris Uni-Core device; Whatman, GE Healthcare, Buckinghamshire, UK). As HC2 and Cobas®4800 test used the same buffer, those tests shared nine punched disks while the careHPV™...
assays used another six disks. This allowed us to obtain the required testing concentration for each of the HPV assays. The FTA card was chemically treated with proprietary reagents that lyse cells upon contact, causing the release of nucleic acids. DNA was recovered from the FTA elute matrix through a simplified elution process using heat and water. Inhibitory components, such as hemoglobin, were retained on the FTA elute matrix.

The six disks and nine disks were transferred into separate 1.5-ml microfuge tubes. Five hundred microliter of sterile water was added to each tube, and the tubes were immediately pulse vortexed for 15 s. Water was removed with a sterile fine-tip pipette. This process was performed twice. Sixty microliter of DCM preservative solution and 90 µl of DEPC water were added to each tube. Both tubes were centrifuged for 30 s and transferred to a heating block at 95 °C for 30 min. During the incubation period, both tubes were centrifuged for 30 s every 10 min to minimize condensation. At the end of the heating process, both tubes were pulse vortexed approximately 30 s and centrifuged for 30 s. The eluted DNA was placed into new microcentrifuge tubes and stored at −80 °C until analysis. Finally, 50 µl of the eluate originating from the nine disks was used for HC2 and 25 µl was used for Cobas®4800. Similarly, 50 µl of the eluate from the six disks was used for the careHPV™ assay. Thereafter, PCR amplification was performed to acquire final results for Cobas®4800 test.

Statistical analysis
The primary objective of this study was to evaluate the sensitivity and specificity of FTA card-based sampling for the detection of CIN2+. According to previous studies, we assumed that the sensitivity of detecting CIN2+ would range from 0.85 to 0.96, the specificity of detecting CIN2+ would range from 0.60 to 0.80, and the CIN2+ prevalence would be approximately 4%. Given these parameters, we calculated a necessary sample size of 375 with an alpha of 0.05 and 80% power [19]. Assuming a 5% testing failure rate, a maximum of 395 women was required. Demographic information such as age, marital status, educational level, occupation, and sexual history was quantified. The accuracy of each combination of different sampling media and downstream HPV testing methods was presented as sensitivity, specificity, and positive and negative predictive values. Proportions were compared using the Fisher’s exact test. SAS 9.2 was used to analyze data (SAS Institute, Cary NC). The 95% confidence interval (95% CI) was calculated using the Wald test by OpenEpi Version 3 (www.OpenEpi.com), an open source epidemiologic statistics for public health. Statistical significance was assessed by two-tailed tests with an alpha level of 0.05.

Results
Demographic information
A total of 3191 women were invited to participate in screening through the LCMCCSS study in 2012, among which 370 (11.7%) refused to participate. The participants had a higher marriage rate (96.7% vs. 93.8%, P = 0.005) and a lower smoking rate (0.3% vs. 1.6%, P = 0.003) than non-participants. Based on their test results, 1392 women were referred for colposcopy, among which 106 (7.6%) refused to return. The women who returned for colposcopy (n = 1286) had a lower smoking rate (0.1% vs. 1.9%, P = 0.016) and fewer live births (<3 live births: 91.2% vs. 84.9%, P = 0.031) compared to those who refused to return. For this study, 396 women, with a mean age of 43.7 ± 8.9 years, were recruited from among the women who were referred for colposcopy. All of the subjects were married and the average ages of initiation of sexual activity and menarche were 20.2 ± 2.2 years and 15.5 ± 1.7 years, respectively. More than half of the women (56.5%) reported primary school as their highest educational level, 33% reported middle school, and only 10.5% reported high school or college education. The majority were farmers or housewives (73.5%), non-smokers (99.3%), and non-drinkers (86.4%). Ninety-seven percent (96.9%) of the women reported having three or less sexual partners, 62.7% had three or less pregnancies, and 85.4% had three or fewer live births (Table 1).

Pathological confirmation and valid cases
Of the 396 samples, 17 were used for careHPV™ pilot testing. In addition, eight FTA card samples and three DCM samples did not provide valid results for the Cobas®4800 test. Therefore, our final analysis was conducted using 368 samples that had valid results for all three HPV tests. Specifically, 34 cases were diagnosed as CIN Grade 1 (CIN1), nine as CIN Grade 2 (CIN2), two as CIN Grade 3 (CIN3), and one case as High Grade Cervical Glandular Intraepithelial Neoplasia (HCGIN).

HPV positivity and accuracy of detecting CIN2+ for different screening methods
VIA showed a high specificity (95.8%) for detecting CIN2 or worse (CIN2+) lesions, but a low sensitivity (8.3%). Only one of 12 CIN2+ cases was identified by VIA. HPV prevalence and the accuracy of detecting CIN2+ lesions for six combinations of two sampling media with three HPV testing methods are shown in Table 2. The liquid samples showed comparable HPV positivity among HC2 (30.4%), careHPV™ (28.8%) and Cobas®4800 (32.1%) tests. Compared to the liquid samples, FTA-based samples showed lower HPV positivity for HC2 (22.8%) and careHPV™ (23.9%), but a higher HPV positivity for Cobas®4800 test (39.4%). The FTA card evidenced higher specificity for the HC2 test compared to
Table 1 Demographic information of the participants

| Variable                      | Value           |
|-------------------------------|-----------------|
| Age (Mean ± SD)               | 43.7 ± 8.9      |
| Age of sexual debut (Mean ± SD)| 20.2 ± 2.2      |
| Age of menarche (Mean ± SD)   | 15.5 ± 1.7      |
| Marriage (YES, %)             | 100             |
| Highest education level (%)   | Primary school: 56.5, Middle school: 33, High school and above: 10.5 |
| Occupation, (%)               | Farmer: 39.8, Housewife: 33.7, Other: 26.5 |
| Smoking (NO, %)               | 99.3            |
| Drinking (NO, %)              | 86.4            |
| Oral contraceptive (YES, %)   | 1.9             |
| Sexual partner (n ≥ 3, %)     | 3.1             |
| No. of pregnancies (%)        | ≤ 3: 62.7, > 3: 37.3 |
| No. of live births (%)        | ≤ 3: 85.4, > 3: 14.6 |

SD standard deviation and standard error of the mean.

Table 2 Accuracy of detecting CIN2+ for different sampling media in combination with three HPV testing methods

| Methods       | Sampling Medium | HPV Prevalence (%) | Accuracy | Sensitivity | Specificity | Positive Predictive Value | Negative Predictive Value |
|---------------|-----------------|--------------------|----------|-------------|-------------|---------------------------|---------------------------|
|               |                 |                   |          | % (n/N)     | % (n/N)     | % (n/N)                   | % (n/N)                   |
| HC2           | FTA             | 22.8               | 91.7 (11/12) | 76.1 ~ 100.0 | 79.5 (283/356) | 75.3 ~ 83.7 | 13.1 (11/112) | 5.9 ~ 20.3 |
|               | Liquid          | 30.4               | 91.7 (11/12) | 76.1 ~ 100.0 | 71.6 (255/356) | 66.9 ~ 76.3 | 9.8 (11/112) | 4.3 ~ 15.3 |
| careHPV™      | FTA             | 23.9               | 83.3 (10/12) | 62.2 ~ 1000 | 78.1 (278/356) | 73.8 ~ 82.4 | 11.4 (10/98) | 4.8 ~ 18   |
|               | Liquid          | 28.8               | 83.3 (10/12) | 62.2 ~ 1000 | 73.0 (260/356) | 68.4 ~ 77.6 | 9.4 (10/106) | 3.8 ~ 15   |
| Cobas®4800    | FTA             | 39.4               | 91.7 (11/12) | 76.1 ~ 1000 | 62.4 (222/356) | 57.4 ~ 67.4 | 7.6 (11/145) | 3.3 ~ 11.9 |
|               | Liquid          | 32.1               | 91.7 (11/12) | 76.1 ~ 1000 | 69.9 (249/356) | 65.1 ~ 74.7 | 9.3 (11/118) | 4.1 ~ 14.5 |

95 % CI 95 % confidence interval, FTA Whatman Indicating FTA Elute® card, HC2 Hybrid capture 2
(91.7 % vs. 53.8 %) compared to the Dutch study. Different workflows, sample sizes and sample utilization may explain this discrepancy. In this study, FTA card-based samples were expected to be eluted to HPV concentrations comparable to those from DCM preservative solution for the HC2 and careHPV™ assays. However, concentration discrepancies remained when transferring samples from solid to liquid, which resulted in a relatively lower HPV positivity and a higher specificity for FTA card-based samples. careHPV™ demonstrated a relatively lower sensitivity than that of HC2, both in our study (careHPV™ vs. HC2: 83.3 % vs. 91.7 %) and in previous studies (careHPV™ vs. HC2: 90.0 % vs. 96.3 %) [16, 20]. However, considering the simplicity of sample transportation and storage, lower costs, and simpler administration, it is nonetheless a promising tool for future large scale cervical cancer screening projects, particularly in low resource settings.

Good agreement between liquid-based media and FTA cards was previously reported for several PCR-based methods, including GP5+/6+, SPF(10) PCR/DEIA/LiPA(25), and real-time PCR assays [7, 8, 12]. However, limited studies have investigated the accuracy of the combination of FTA cards and PCR-based methods for CIN2+ detection. A Spanish study showed that the combination of FTA cards and GP5+/6+ or SPF(10) HPV testing provided a sensitivity of 95.9–98.0 % and a specificity of 42.9–48.1 % for CIN2+ detection [11]. Our study is the first to explore the accuracy of FTA cards in combination with the Cobas®4800 test for CIN2+ detection. As the manufacturer did not provide instructions for DCM-based sample detection, CICAMS developed the workflow based on several small pilot studies. Specifically, samples used for PCR amplification from FTA cards had a much higher HPV concentration compared to samples from DCM preservative solution (3.6 % vs. 0.5 %), resulting in a high sensitivity (91.7 %). As a result, a higher HPV positivity and a lower specificity were found for FTA card-based samples compared to DCM samples. Further study is needed to optimize the workflow for Cobas®4800 testing using FTA card-based samples in order to reduce false positives and improve the specificity. Moreover, although this result was comparable with previous studies (70.97 %) of Cobas®4800 test in China [21] and other PCR-based methods (42.9–48.1 %) [11], one needs to take into consideration additional triage biomarkers in order to reduce the referral rate for

### Table 3 CIN2+ case detection by different combinations of HPV testing methods and sampling media

| ID no. | Pathological result | HC2 (Rlu/PC) Liquid | FTA | careHPV™ (Rlu/PC) Liquid | FTA | Cobas® 4800 Liquid | FTA |
|--------|---------------------|--------------------|-----|--------------------------|-----|-------------------|-----|
| 447    | CIN2                | 0.20*              | 181.73 | 0.42*               | 17.11 | POS               | POS |
| 445    | CIN3                | 99.90              | 22.42 | 51.31                   | 28.50 | POS               | POS |
| 444    | CIN2                | 472.51             | 650.36 | 170.00                 | 173.28 | POS               | POS |
| 442    | CIN2                | 675.40             | 325.26 | 117.93                 | 140.85 | POS               | POS |
| 448    | CIN2                | 451.36             | 43.57  | 104.47                 | 34.00  | POS               | POS |
| 441    | CIN2                | 2003.50            | 19.03  | 150.79                 | 37.03  | POS               | POS |
| 446    | CIN2                | 4.26               | 0.28a  | 1.39                    | 0.58a  | POS               | POS |
| 443    | CIN2                | 463.18             | 150.22 | 80.80                   | 89.48  | POS               | POS |
| 450    | CIN2                | 1031.00            | 92.23  | 100.65                 | 61.33  | POS               | POS |
| 240    | HCGIN               | 1.05               | 1.34   | 0.29b                   | 0.78b  | NEGa              | NEGa |
| 288    | CIN3                | 26.62              | 1.42   | 20.65                   | 3.71   | POS               | POS |
| 344    | CIN2                | 5.00               | 50.89  | 2.68                    | 29.71  | POS               | POS |

CIN2 cervical intraepithelial neoplasia grade 2, CIN3 cervical intraepithelial neoplasia grade 3, HCGIN high grade cervical glandular intraepithelial neoplasia, FTA Whatman Indicating FTA Elute® card, HC2 Hybrid capture 2, NEG negative result, POS positive result, RLU/PC the ratio of relative light units to standard positive control, cut-point: 1.0

* CIN2+ case failed to be detected

### Table 4 Performance and discrepancies between two specimen storage methods for three HPV testing assays

| Test assays | FTA sample | Liquid sample | Subtotal | Agreement |
|-------------|------------|---------------|----------|-----------|
|             |            |               |          | %         | 95 % CI   |
| HC2         | Positive   | Negative      | 90.2     | 87.2      | 93.3      |
|             | Positive   | Negative      | 80       | 4         | 84        |
|             | Negative   | 32             | 252      | 284       |
|             | Subtotal   | 112            | 256      | 368       |
| careHPV™    | Positive   | Negative      | 83.7     | 79.9      | 87.5      |
|             | Positive   | 67             | 21       | 88        |
|             | Negative   | 39             | 241      | 280       |
|             | Subtotal   | 106            | 262      | 368       |
| Cobas4800   | Positive   | Negative      | 85.6     | 82.0      | 89.2      |
|             | Positive   | 105            | 40       | 145       |
|             | Negative   | 13             | 210      | 223       |
|             | Subtotal   | 118            | 250      | 368       |
colposcopy. Furthermore, Cobas®4800 testing identified all of the squamous epithelial lesions but missed one glandular epithelial lesion (one case of HCGIN). This reflects the general deficiency of HPV DNA based screening methods, and need for complementary cytology.

This is the first report of a study comparing three downstream HPV testing methods with clinical implications by FTA cards and conventional liquid based sampling media. This study explored experimental workflows for the careHPV™ and Cobas®4800 tests and optimized the current workflow for the HC2 test, which provides data for future laboratory investigations. Moreover, this study differs from previous reports which used PreservCyt (Hologic, Bedford, MA) medium for a single test; this study is the first to compare the accuracy of the FTA card and DCM preservative solution combined with three clinical HPV DNA tests in cervical cancer screening. This study has some limitations that must be addressed as well. First, our study was based on a referral population that was triaged for colposcopy. A higher HPV prevalence was found in this group compared to the general population, which had an impact on the accuracy parameters for detecting CIN2+ lesions. Second, this study is a hospital-based pilot study with a relatively small sample size. We therefore lacked statistical power to assess test characteristics among sub-groups. Third, the Cobas®4800 test workflow requires further optimization for future large-scale studies. Fourth, we did not consider the sequence of sample collection. Taking two samples with a short time interval might have a negative impact on the accuracy of the second sample. However, the second sample, which was collected on FTA cards, showed comparable accuracy for detecting CIN2+. This indicates that FTA cards have a robust capacity for capturing samples. Future studies should further evaluate the accuracy of these two sampling media in a random sampling sequence to avoid any potential bias. Fifth, we made a parallel comparison for three HPV testing methods on a single FTA card, which may result in insufficient distribution of sample for each test. Additionally, reproducibility studies were not feasible in this study. Finally, there are several types of cervical cytological sampling brushes, but this study only used a conical cervical sampler for sample collection. Future comparisons of different cytological samplers need to be investigated to identify the samplers that provide the highest degree of accuracy.

This work also draws a promising picture for future large-scale cervical cancer screening projects. As dried material on a solid carrier is neither hazardous nor contagious, applying genital self-samples on FTA cards can solve storage and transportation problems encountered in developing regions. With further optimization and automation of the experimental procedures, FTA cards in combination with careHPV™ could be used for cervical cancer screening in remote areas, and FTA cards in combination with HC2 or Cobas®4800 could be used in metropolitan areas. Our previous study demonstrated that the agreement between self-collected and clinician-collected specimens on FTA cards was very good and the acceptability of FTA card-based self-collection was reasonably high [5, 6]. Therefore, future studies should focus on a feasibility and accuracy evaluation of FTA-card based self-sampling in cervical cancer screening. It is possible that, in the future, women will be able to self-sample at home, and mail the sample to the regional central laboratory for sample analysis. Doctors would only call back those with positive result for colposcopic examination. Consequently, limited healthcare resources could be focused on high-risk populations, thereby increasing the coverage of current screening initiatives. Additionally, previous studies demonstrated acceptable performance of FTA cards in humid tropical climates with self-collection, which also provides this solid sample carrier a promising future in cervical cancer screening in low-resource areas [8, 22].

Conclusions

Our study provided clinical evidence for evaluating the accuracy of FTA card-based sampling as an alternative to the liquid-based sampling in cervical cancer screening. With further optimization of the experimental workflow, FTA cards can be paired with different HPV DNA testing methods suitable a variety of economic conditions, thereby providing new possibilities for large-scale population-based cervical cancer screening.

Abbreviations

CICAMS: Cancer Institute, Chinese Academy of Medical Sciences; CIN: Cervical Intraepithelial Neoplasia; CIN1: CIN Grade 1; CIN2: CIN Grade 2; CIN2+: CIN2 or worse; CIN3: CIN Grade 3; FTA card: Whatman Indicating FTA Elute® card; HC2: Hybrid Capture 2; HCGIN: High Grade Cervical Glandular Intraepithelial Neoplasia; HPV: Human Papillomavirus; NPV: Negative predictive value; PATH: Program for Appropriate Technology in Health; PPV: Positive Predictive Value; VIA: Visual Inspection with Acetic Acid.

Competing interests

This study was supported by a basic research grant from CICAMS (JK2011B20) for Dr. Shang-Ying Hu, and a research grant (2012-0057) from the Investigator Initiated Studies Program of GE (China) Research and Development Center Co. Ltd for Dr. You-Lin Qiao. All the authors declare that they have no competing interests.

Authors’ contributions

Shao-Ming Wang analyzed the data, generated the tables, figures and wrote the manuscript. Shang-Ying Hu made important contributions on the data analysis sections and field work. Wen Chen and Feng Chen made substantial contributions to explore the experimental workflow for FTA-based sample detection, and provided experimental insight on the result interpretation. Fang-Hui Zhao and You-Lin Qiao helped design the study and made comments regarding the intellectual content. Wei He, Xin-Ming Ma, Yu-Qing Zhang and Jian Wang conducted the experiments and helped interpret the
data in a meaningful way. Priya Sivasubramaniam helped review and revise the manuscript. All authors read and approved the final manuscript.

Acknowledgements
This study was supported by a basic research grant from CICAMS (JK2011B20), and a research grant (2012-0057) from the Investigator Initiated Studies Program of GE (China) Research and Development Co. Ltd. Dr. Danny V. Colombaro is gratefully acknowledged for reviewing this manuscript. Colleagues of the TongGu Women and Children’s hospital of China and all the women involved in this study are acknowledged for their participation.

Author details
1 Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, P.O. Box 225817 South Panjayanu Lane, Beijing 100021, China.
2 Beijing Municipal Institute of Labour Protection, Beijing 100021, China.
3 Vanderbilt University School of Medicine, Nashville, TN 37212, USA.

Received: 2 February 2015 Accepted: 30 October 2015
Published online: 04 November 2015

References
1. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132:1133–45.
2. Ferlay J, Soer J, Parkin D, Jemal A. Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon: France; International Agency for Research on Cancer; Available from: http://globoCAN.iarc.fr, accessed on 15/01/2015.
3. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.
4. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco P, Mason M, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008;26 Suppl 10:S29–41.
5. Guan Y, Gravitt PE, Howard R, Eby YJ, Wang S, Li B, et al. Agreement for HPV genotyping detection between self-collected specimens on a FTA cartridge and clinician-collected specimens. J Virol Methods. 2013;189:167–71.
6. Guan Y, Castle PE, Wang S, Li B, Feng C, Cai B, et al. Agreement for HPV genotyping detection between self-collected specimens on a FTA cartridge and clinician-collected specimens. J Virol Methods. 2013;189:167–71.
7. Gustavsson I, Lindell M, Wålander E, Strand A, Gyllensten U, et al. A cross-sectional study on the acceptability of self-collection for HPV testing among women in rural China. Sex Transm Infect. 2012;88:490–4.
8. Heideman DA, Hesselink AT, Berkhof J, van Kemenade F, Melchers WJ, et al. Clinical validation of the cobas 4800 high-risk HPV test as a tool in cervical cancer screening and cytology triage. J Clin Virol. 2013;57:125–9.
9. Pretorius RG, Zhang WH, Belinson JL, Huang MN, Wu LY, Zhang X, et al. Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. Am J Obstet Gynecol. 2004;191:430–4.
10. Qiao YL, Sellers JR, Eder PS, Bao YP, Lim JM, Zhao FH, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol. 2008;9:929–36.
11. Heideman DA, Hesselink AT, Berkhoff J, van Kemenade F, Melchers WJ, Daalmeijer NF, et al. Clinical validation of the cobas 4800 HPV test for cervical screening purposes. J Clin Microbiol. 2011;49:3983–5.
12. Castle PE, Sadorra M, Lau T, Aldrich C, Garcia FA, Kornegay J. Evaluation of a prototype real-time PCR assay for carcinogenic human papillomavirus (HPV) detection and simultaneous HPV genotype 16 (HPV16) and HPV18 genotyping. J Clin Microbiol. 2009;47:3944–7.
13. Liu J, Fine J. On sample size for sensitivity and specificity in prospective diagnostic accuracy studies. Stat Med. 2004;23:2537–50.
14. Zhao FH, Lin MJ, Chen F, Hu SY, Zhang R, Belinson JL, et al. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol. 2010;11:1160–71.
15. Chen W, Yu LL, Wang H, Fu CJ, Chen F, Cao YQ, et al. Evaluation of cobas 4800 high-risk HPV test as a tool in cervical cancer screening and cytology triage. Zhonghua Zhong Liu Za Zhi. 2012;34:543–8.
16. Phongsavan K, Gustavsson I, Marions L, Phengsavanh A, Wahlstrom R, Gyllensten U. Detection of human papillomavirus among women in Laos: feasibility of using filter paper card and prevalence of high-risk types. Int J Gynecol Cancer. 2012;22:398–406.

Submit your next manuscript to BioMed Central
and take full advantage of:
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit